JUL 06, 2015 02:20 PM PDT

Beating Blood Cancer - Repurposefully

A drug that has been used to treat rheumatoid arthritis may find a new niche in treating blood cancers at a fraction of the cost, according to British researchers.
Drug for arthritis may help blood cancer too.
According to an article in Futurity.org, myeloproliferative neoplasms (MPNs) cause an overproduction of blood cells resulting in symptoms that include night sweats, itching, and tiredness. Usually occurring in people in their 50s and 60s, MPNs are currently treated with aspirin, removal of excess blood and mild chemotherapy. A new drug, Ruxolitinib, is effective, but it costs more than $62,370 per patient per year and has yet to be approved by the National Institute for Health and Care Excellence (NICE) (http://www.futurity.org/methotrexate-blood-cancers-953662/?utm_source=feedly&utm_medium=webfeeds).

Martin Zeidler of the biomedical science department at University of Sheffield and his colleagues think they have a better answer. In a study funded by Cancer Research UK and published in PLOS ONE, they show that Methotrexate (MTX) can work in the same way. Using cells from the fruit fly Drosophila, they screened for small molecules that suppress the signaling pathway central to the development of MPNs in humans. After further testing, they confirmed this in human cells, "even those carrying the mutated gene responsible for MPNs in patients."

According to Zeidler, "Given that a year's course of low-dose MTX costs around £30 [$47], the potential to repurpose MTX could provide thousands of patients with a much needed treatment option and also generate substantial savings for health care systems. Because MTX is a World Health Organization ‘essential medicine,' this also means that this well understood drug could be used throughout the developing world."

Zeidler explains that MTX can be used at low doses to treat inflammatory diseases including rheumatoid arthritis, Crohn's disease and psoriasis and has few side effects and that it is also used in some cancers at much higher doses where the side effects are substantial and similar to other chemotherapies. Now working with clinical colleagues at the Royal Hallamshire Hospital, he is attempting to do clinical trials to examine the possibility of repurposing low-dose MTX for the treatment of MPNs.

As Zeidler says, "We have the potential to revolutionize the treatment of this group of chronic diseases-a breakthrough that may ultimately represent a new treatment option able to bring relief to both patients and health funders."

According to Nell Barrie, senior science information manager at Cancer Research UK, "Finding new uses for existing drugs is a great way to speed up improvements in treatment, as these drugs will have previously been through safety tests. Methotrexate is already used as a chemotherapy drug for several types of cancer, and this early research shows that at much lower doses it could have the potential to help treat certain blood disorders."

As explained by the Mayo Clinic, "Methotrexate belongs to the group of medicines known as antineoplastics (cancer medicines). It blocks an enzyme that is needed by cells to live. This interferes with the growth of cancer cells, which are eventually destroyed by the body. For patients with arthritis or psoriasis, methotrexate may work by improving the immune system." Methotrexate injection "is used alone or together with other medicines to treat several types of cancer," including breast, head and neck, lung, blood, bone, lymph node and uterine. It is also "used to treat adults with severe rheumatoid arthritis and children with polyarticular juvenile idiopathic arthritis who had other treatments that did not work well" and to control symptoms of severe psoriasis "in adults who have not been helped by other treatments" (http://www.mayoclinic.org/drugs-supplements/methotrexate-injection-route-subcutaneous-route/description/drg-20064776).

The Mayo Clinic also says, "Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUL 25, 2018
Neuroscience
JUL 25, 2018
Can CT Scans Increase the Risk of Brain Cancer?
Medical imaging has gone from fuzzy X-rays that didn't show much, to real-time functional MRI scans in just a few decades. Being able to see inside the...
SEP 15, 2018
Cancer
SEP 15, 2018
Undescended testicles could lead to testicular cancer and infertility in adult males
An undescended testis (cryptorchidism) is a condition in which one of the testes or both have not descended into the right position in the scrotum at birth and either stay at the abdomen or d...
OCT 08, 2018
Immunology
OCT 08, 2018
Natural Killer Cells to Aid in Cancer Therapy
Researchers utilize nanoparticles to stimulate NK cells that induce tumor cells to express PDL1, a protein involved in immune response messaging...
OCT 31, 2018
Cancer
OCT 31, 2018
Researchers identify a protein marker that induces dormancy in metastatic breast cancer
Researchers at the Mount Sinai hospital identified for the first time a protein marker that could indicate whether breast cancer will further metastasize or remains in a dormant state accordi...
NOV 22, 2018
Cell & Molecular Biology
NOV 22, 2018
Stopping Cancer Cells in Their Tracks
Researchers at the University of Minnesota have developed a technique to stop the movement of cancer cells....
DEC 04, 2018
Immunology
DEC 04, 2018
Why is Skin Cancer so Elusive?
A pathway involved in skin cancer reveals a potential immunotherapy target...
Loading Comments...